- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00489554
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
December 30, 2019 updated by: GlaxoSmithKline
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Mexican infants with pneumococcal conjugate vaccine GSK 1024850A co-administered with a diphtheria, tetanus, acellular pertussis (DTPa)-combined vaccine (Infanrix hexa) and rotavirus vaccine (Rotarix) in children during the first 6 months of age.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Study Type
Interventional
Enrollment (Actual)
230
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico, Mexico, 14000
- GSK Investigational Site
-
Mexico city, Mexico, 14000
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 2 months (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects between and including 6-12 weeks of age at the time of the first vaccination.
- Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
- Written informed consent obtained from the parent or guardian of the subject.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- Born after a gestation period of 36 to 42 weeks inclusive.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccines and ending 7 days after dose 1 and dose 2 and one month after dose 3.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
- A family history of congenital or hereditary immunodeficiency.
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- Previous vaccination against diphtheria, tetanus, pertussis, polio, hepatitis B, Haemophilus influenzae type b, rotavirus and/or Streptococcus pneumoniae; with the exception of vaccines where the first dose may be given at birth within the first two weeks of life according to national recommendations (e.g. Hepatitis B and BCG).
- History of, or intercurrent, diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type b disease.
- Gastroenteritis within 7 days preceding the study vaccine administration (warrants deferral of the vaccination).
- Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal (GI) tract, intussusception (IS) or other medical condition determined to be serious by the investigator.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
- History of any neurological disorders or seizures.
- Major congenital defects or serious chronic illness.
- Acute disease at the time of enrolment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Synflorix Vaccine Group
Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
|
Intramuscular injection, 3 doses.
Other Names:
Intramuscular injection, 3 doses.
Oral, 2 doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibody Concentrations Against Pneumococcal Vaccine Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Concentrations were expressed as geometric mean concentration (GMC).
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Antibody Concentrations Against Protein D
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Concentrations were given as geometric mean concentration (GMC) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opsonophagocytic Titer Against Pneumococcal Vaccine Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects With Anti-pneumococcal Vaccine Serotypes Antibody Concentrations Greater Than or Equal to 0.2 Microgram Per Milliliter
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Antibody concentrations were expressed as Geometric Mean Concentrations against pneumococcal cross-reactive serotypes 6A and 19A.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Opsonophagocytic Titer Against Pneumococcal Cross-reactive Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
The results were presented as the geometric mean dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Seropositive Against Vaccine Pneumococcal Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter.
The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Seropositive for Opsonic Titer Against Vaccine Pneumococcal Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Seropositivity was defined as an opsonic titer greater than or equal to 8. The vaccine pneumococcal serotypes assessed include 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Seropositive Against Cross-reactive Pneumococcal Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Seropositivity was defined as anti-pneumococcal antibody concentration greater than or equal to 0.05 microgram per milliliter.
The cross-reactive pneumococcal serotypes assessed include 6A and 19A.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Seropositive for Opsonic Titer Against Cross-reactive Pneumococcal Serotypes
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Seropositivity was defined as anti-pneumococcal antibody opsonic titer greater than or equal to 8. The vaccine pneumococcal cross-reactive serotypes assessed include 6A and 19A.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Seropositive for Anti-Protein D Antibodies
Time Frame: One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Seropositivity was defined as antibody concentration greater than or equal to 100 Enzyme-Linked Immuno Sorbent Assay (ELISA) units per milliliter.
|
One month after the administration of the 3rd vaccine dose i.e. Month 5
|
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Time Frame: Within 4 days following any vaccine dose
|
Grade 3 redness and swelling was > 30 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful.
Any was occurrence of any local symptom regardless of grade and whatever the number of injections.
|
Within 4 days following any vaccine dose
|
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Time Frame: Within 4 days following any vaccine dose
|
Any fever was defined as axillary temperature ≥ 37.5 degree centigrade (°C), grade 3 fever was axillary temperature > 39.5°C.
Grade 3 drowsiness, irritability, and loss of appetite was general symptom which prevented normal everyday activities.
Grade 3 diarrhea was ≥ 6 looser than normal stools/day and Grade 3 vomiting was ≥ 3 episodes of vomiting/day.
Related was solicited general symptom considered by the investigator to have a causal relationship to study vaccination.
|
Within 4 days following any vaccine dose
|
Number of Subjects Reporting Any Unsolicited AEs
Time Frame: Within 31 days after any vaccine dose
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
Within 31 days after any vaccine dose
|
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Time Frame: Up to Month 5
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
Up to Month 5
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Silfverdal SA, Coremans V, Francois N, Borys D, Cleerbout J. Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Expert Rev Vaccines. 2017 Feb;16(2):109-121. doi: 10.1586/14760584.2016.1164044. Epub 2016 Sep 30.
- Ruiz-Palacios G et al. Immunogenicity, safety and reactogenicity of the new 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in Mexican infants. Abstract presented at the XIII Congreso Latinoamericano de Infectología Pediátrica (SLIPE). Guayaquil, Ecuador, 12-15 August 2009.
- Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, Lavalle-Villalobos A, Casas-Munoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011 Nov;7(11):1137-45. doi: 10.4161/hv.7.11.17984. Epub 2011 Nov 1.
- Schuerman L et al. Population variability in antibody responses following pneumococcal conjugate vaccination: experience with the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
- Schuerman L et al. Population variability of opsonophagocytic activity following 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate (PHiD-CV) vaccination more limited than antibody responses. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 3, 2007
Primary Completion (Actual)
March 31, 2008
Study Completion (Actual)
March 31, 2008
Study Registration Dates
First Submitted
June 20, 2007
First Submitted That Met QC Criteria
June 20, 2007
First Posted (Estimate)
June 21, 2007
Study Record Updates
Last Update Posted (Actual)
January 13, 2020
Last Update Submitted That Met QC Criteria
December 30, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia, Pneumococcal
- Streptococcal Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- 109661
- 2015-001510-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD is available via the Clinical Study Data Request site (click on the link provided below).
IPD Sharing Time Frame
IPD is available via the Clinical Study Data Request site (click on the link provided below).
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Study Data/Documents
-
Statistical Analysis Plan
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 109661Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Streptococcus Pneumoniae Vaccines
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae VaccinesSweden
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalMexico
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalVietnam
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalGermany
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalPoland
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalSpain, Greece
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalRussian Federation, Poland
-
Universidad de la SabanaRecruitingCommunity-acquired Pneumonia | Streptococcus Pneumoniae Infection | Streptococcus Pneumoniae Pneumonia | Streptococcus Pneumoniae Infection InvasiveColombia
-
PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedStreptococcus Pneumoniae InfectionsChina
Clinical Trials on Synflorix
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalRussian Federation, Poland
-
GlaxoSmithKlineTerminatedInfections, StreptococcalPhilippines
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalMexico
-
PATHCompletedPneumonia, PneumococcalGambia
-
GlaxoSmithKlineCompletedInfections, StreptococcalKorea, Republic of
-
GlaxoSmithKlineWithdrawnImmunisation Against Streptococcus Pneumoniae
-
Papua New Guinea Institute of Medical ResearchThe University of Western AustraliaUnknownPneumonia | Sepsis | Meningitis | Otitis Media | BacteraemiaPapua New Guinea
-
GlaxoSmithKlineCompletedStreptococcus Pneumoniae Vaccines | Infections, StreptococcalVietnam
-
GlaxoSmithKlineCompletedInfections, StreptococcalChile
-
GlaxoSmithKlineWithdrawnInfections, Rotavirus